Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Duration of androgen suppression in prostate cancer.

Badiozamani KR.

N Engl J Med. 2009 Sep 17;361(12):1212; author reply 1212-3. doi: 10.1056/NEJMc091433. No abstract available.

2.

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.

Seruga B, Tannock IF.

Nat Clin Pract Oncol. 2008 Oct;5(10):574-6. doi: 10.1038/ncponc1180. Epub 2008 Jul 15. No abstract available.

PMID:
18628739
3.

Intermittent complete androgen blockade in metastatic prostate cancer.

Rambeaud JJ.

Eur Urol. 1999;35 Suppl 1:32-6. Review.

PMID:
10081701
4.

Intermittent androgen suppression in prostate cancer: the Canadian experience.

Hurtado-Coll A, Goldenberg SL, Gleave ME, Klotz L.

Urology. 2002 Sep;60(3 Suppl 1):52-6; discussion 56. Review.

PMID:
12231049
5.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
6.

Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.

Kaneko Y, Maekawa S, Arakaki R, Okada Y, Terada N, Nishimura K.

Hinyokika Kiyo. 2006 Apr;52(4):259-64.

7.

Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones C, Asbell SO, Valicenti RK, Han S, Thomas CR Jr, Shipley WS; Radiation Therapy Oncology Group 9413.

J Clin Oncol. 2003 May 15;21(10):1904-11.

PMID:
12743142
8.

A call for more with a desire for less: pelvic radiotherapy with androgen deprivation in the treatment of prostate cancer.

Pollack A.

J Clin Oncol. 2003 May 15;21(10):1899-901. No abstract available.

PMID:
12743140
9.

Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.

Yoon FH, Gardner SL, Danjoux C, Morton G, Cheung P, Choo R.

J Urol. 2008 Oct;180(4):1438-43; discussion 1443-4. doi: 10.1016/j.juro.2008.06.029. Epub 2008 Aug 16.

PMID:
18710743
10.

This paper evaluates the natural history of prostate cancer in heterogeneous cohort of men treated with HT.

Yossepowitch O.

Eur Urol. 2007 Aug;52(2):453. No abstract available.

PMID:
17674435
11.
12.

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C.

Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21.

PMID:
19249153
14.

[Therapy of nodal positive prostatic carcinoma: when should hormone therapy be started?].

Zierhut D.

Strahlenther Onkol. 1998 Jul;174(7):382-3. German. No abstract available.

PMID:
9689961
15.

[Proton hypophysectomy and subtotal body irradiation in combined treatment of stage IV prostate cancer].

Aleksandrov VP, Kondrat'eva EA, Karelin MI, Konnov BA, Zharinov GM, Metelev VV, Pecherskiń≠ AV.

Urologiia. 1999 Nov-Dec;(6):26-8. Russian. No abstract available.

PMID:
16859000
16.

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature.

Abrahamsson PA.

Eur Urol. 2010 Jan;57(1):49-59. doi: 10.1016/j.eururo.2009.07.049. Epub 2009 Aug 7. Review.

PMID:
19683858
17.

Duration of androgen suppression in the treatment of prostate cancer.

Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM, Musat E, Piérart M, Mauer ME, Collette L; EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group.

N Engl J Med. 2009 Jun 11;360(24):2516-27. doi: 10.1056/NEJMoa0810095.

19.

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.

Salonen AJ, Viitanen J, Lundstedt S, Ala-Opas M, Taari K, Tammela TL; FinnProstate Group.

J Urol. 2008 Sep;180(3):915-9; discussion 919-20. doi: 10.1016/j.juro.2008.05.009. Epub 2008 Jul 17.

PMID:
18635219
20.

Supplemental Content

Support Center